Letermovir

来特莫韦

Report date: 2026/05/24 20:00:34
NMEFirst In Class

Base Information

Drug NameLetermovir
Drug Alias Name莱特莫韦letermovirletermovirumPrevymis普瑞明 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman cytomegalovirus tripartite terminas inhibitors
TargetsHuman cytomegalovirus tripartite terminas
Therapy Area/IndicationsRejection of pancreatic transplantationRejection of renal transplantationRejection of lung transplantation +[16] 
Global Approved IndicationsCytomegalovirus Infections
Approved Indications in ChinaCytomegalovirus Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2017/11/08
Country/TerritoryUnited StatesPolandTurkey +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAicuris
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of California IrvineMerck Sharp & Dohme CorpMerck Sharp & Dohme Bv +[14] 
Inactive CompaniesMsd International Gmbh T/A Msd Ireland (Ballydine)National Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsRejection of pancreatic transplantationRejection of renal transplantationRejection of lung transplantation +[15] 
Inactive IndicationsInfections

Other Information

ATC CodeJ05AX18
Related LinksWikipediaDrugBankKEGG